ASARM mineralization hypothesis: A bridge too far?

Journal of Bone and Mineral Research

Volumn 25, Issue 4, 2010, Pages 692-694

  David, Valentin ^a   Quarles, L Darryl ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; SCLEROPROTEIN;

AMINO ACID SEQUENCE; BONE MINERALIZATION; NONHUMAN; NOTE; OSTEOBLAST; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; X LINKED HYPOPHOSPHATEMIC RICKETS;

AMINO ACID MOTIFS; ANIMALS; ASPARTIC ACID; BONE AND BONES; CALCIFICATION, PHYSIOLOGIC; EXTRACELLULAR MATRIX PROTEINS; FIBROBLAST GROWTH FACTORS; GLYCOPROTEINS; HUMANS; MICE; PHOSPHATES; PHOSPHOPROTEINS; SERINE;

EID: 77953427179     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.69     Document Type: Note

References (26)

1. Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006;17:1305-1315. (Pubitemid 43673410)
2. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281:6120-6123. (Pubitemid 43847540)
3. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770-774. (Pubitemid 44949607)
4. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest. 2008;118:3820-3828.
5. Quarles LD. Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest. 2003;112:642-646.
6. Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38:1310-1315. (Pubitemid 44646294)
7. Rowe PS, Kumagai Y, Gutierrez G, et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone. 2004;34:303-319. (Pubitemid 38177612)
8. Liu S, Rowe PS, Vierthaler L, Zhou J, Quarles LD. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol. 2007;192:261-267. (Pubitemid 46444416)
9. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab. 2006;291:E38-E49.
10. Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;1310-1315. (Pubitemid 44646294)
11. Guo R, Rowe PS, Liu S, Simpson LG, Xiao ZS, Quarles LD. Inhibition of MEPE cleavage by Phex. Biochem Biophys Res Commun. 2002;297:38-45.
12. Rowe PS, Garrett IR, Schwarz PM, et al. Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone. 2005;36:33-46.
13. Addison W, Masica D, Gray J, McKee MD. Phosphorylation-Dependent Inhibition of Mineralization by Osteopontin ASARM Peptides is Regulated by PHEX Cleavage. J Bone Miner Res. 2009;
14. Xiao ZS, Crenshaw M, Guo R, Nesbitt T, Drezner MK, Quarles LD. Intrinsic mineralization defect in Hyp mouse osteoblasts. Am J Physiol. 1998;275:E700-E708. (Pubitemid 128732059)
15. Addison WN, Nakano Y, Loisel T, Crine P, McKee MD. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res. 2008;23:1638-1649.
16. Martin A, David V, Laurence JS, et al. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology. 2008;149:1757-1772.
17. Rivadeneira F, Styrkarsdottir U, Estrada K, et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet. 2009;41:1199-1206.
18. Liu S, Brown TA, Zhou J, et al. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol. 2005;16:1645-1653. (Pubitemid 41721870)
19. Yuan B, Takaiwa M, Clemens TL, et al. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest. 2008;118:722-734. (Pubitemid 351206560)
20. Yuan B, Feng JQ, Xing Y, Meudt J, Rowe PS, Drezner MK. Aberrant Phex Function in Osteocytes Has Limited Effects on Bone Mineralization in X-Linked Hypophosphatemia (XLH). J Bone Miner Res. 2008; 23.
21. David V, Martin A, Hedge AM, Rowe PS. Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology. 2009;150:4012-4023.
22. Rittling SR, Matsumoto HN, McKee MD, et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res. 1998;13:1101-1111.
23. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest. 1998;101:1468-1478. (Pubitemid 28166845)
24. Yoshitake H, Rittling SR, Denhardt DT, Noda M. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A. 1999;96:8156-8160. (Pubitemid 29328424)
25. Boskey AL, Chiang P, Fermanis A, et al. MEPE's diverse effects on mineralization. Calcif Tissue Int. 2009;86:42-46.
26. Rifas L, Cheng S, Halstead LR, Gupta A, Hruska KA, Avioli LV. Skeletal casein kinase activity defect in the HYP mouse. Calcif Tissue Int. 1997;61:256-259. (Pubitemid 27360820)